Empagliflozin Reduces Arrhythmogenic Effects in Rat Neonatal and Human iPSC-Derived Cardiomyocytes and Improves Cytosolic Calcium Handling at Least Partially Independent of NHE1

Investigators studied whether the SGLT2 inhibitor empagliflozin affected cardiomyocyte electrical activity under hypoxic conditions using rat neonatal and human induced pluripotent stem cell-derived cardiomyocytes.